Nikhil Lalwani
Tracked across 2 events · 13 articles · First seen Apr 20, 2026 · Last active Sep 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Nikhil Lalwani is CEO of ANI Pharmaceuticals; he commented on solid Q1 performance but was not directly involved in the stock sales.
Jul 09, 2026 · 6 articles
Regulatory
ANI Pharmaceuticals received final approval from the U.S. United States — Food and Drug Administration for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2mg, 3mg and 5mg strengths. The product…
Impact: As ANI's President and CEO, Nikhil Lalwani commented on the approval, highlighting the R&D team's execution and the company's target of launching at least 15 new generics in 2026.
Sep 23, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Nikhil Lalwani live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard